Skip to main content
Terug
LJUIF logo

SSY Group Limited

Datakwaliteit: 100%
Overbought
LJUIF
OTC Healthcare Drug Manufacturers - Specialty & Generic
€ 0,40
€ 0,00 (0,00%)
Marktkapitalisatie: 1,19B
Dagbereik
€ 0,40 € 0,70
52-Weeksbereik
€ 0,40 € 0,70
Volume
700
50D / 200D Gem.
€ 0,40 / € 0,48
Vorige Slotkoers
€ 0,40

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E 1,1 0,4
P/B 0,2 2,9
ROE % 15,0 3,7
Net Margin % 18,4 3,9
Rev Growth 5Y % 7,9 10,0
D/E 0,5 0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 € 0,29
€ 0,26 – € 0,33
 5,1 B 1
FY2026 € 0,22
€ 0,20 – € 0,25
 4,8 B 1

Belangrijkste Punten

Revenue grew 7,89% annually over 5 years — modest growth
Earnings declined -19,53% over the past year
ROE of 15,00% — decent returns on equity
Net margin of 18,38% shows strong profitability
Debt/Equity of 0,50 — conservative balance sheet
Negative free cash flow of -49,39M

Groei

Revenue Growth (5Y)
7,89%
Revenue (1Y)-10,67%
Earnings (1Y)-19,53%
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
15,00%
ROIC9,28%
Net Margin18,38%
Op. Margin23,27%

Veiligheid

Debt / Equity
0,50
Current Ratio2,78
Interest Coverage10,59

Waardering

P/E Ratio
1,12
P/B Ratio0,16
EV/EBITDA2,66
Dividend Yield0,03%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -10,67% Revenue Growth (3Y) -5,27%
Earnings Growth (1Y) -19,53% Earnings Growth (3Y) -2,79%
Revenue Growth (5Y) 7,89% Earnings Growth (5Y) 14,75%
Profitability
Revenue (TTM) 5,77B Net Income (TTM) 1,06B
ROE 15,00% ROA 8,42%
Gross Margin 50,37% Operating Margin 23,27%
Net Margin 18,38% Free Cash Flow (TTM) -49,39M
ROIC 9,28% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,50 Current Ratio 2,78
Interest Coverage 10,59 Dividend Yield 0,03%
Valuation
P/E Ratio 1,12 P/B Ratio 0,16
P/S Ratio 0,21 PEG Ratio -0,83
EV/EBITDA 2,66 Dividend Yield 0,03%
Market Cap 1,19B Enterprise Value 3,57B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 5,77B 6,46B 6,43B 5,36B 4,26B
Net Income 1,06B 1,32B 1,12B 785,53M 611,97M
EPS (Diluted) 0,36 0,44 0,38 0,26 0,20
Gross Profit 2,91B 3,62B 3,44B 3,04B 2,58B
Operating Income 1,34B 1,64B 1,42B 988,09M 758,88M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 12,60B 11,97B 10,97B 10,71B 9,25B
Total Liabilities 5,07B 4,70B 4,42B 4,22B 3,34B
Shareholders' Equity 7,22B 6,93B 6,21B 6,22B 5,65B
Total Debt 3,64B 3,37B 3,21B 3,11B 2,44B
Cash & Equivalents 1,26B 1,62B 1,71B 1,69B 1,45B
Current Assets 5,06B 5,12B 4,88B 4,88B 4,26B
Current Liabilities 1,82B 2,52B 2,68B 2,39B 2,12B

Strategiescores

This stock passed the criteria for 2 strategies

Score = fit strength (0–100)
Rank = position among all matches
Custom Contrarian Investing (David Dreman)
#542 of 658
9
Value Defensive Investing (Benjamin Graham)
#498 of 708
18

Recente Activiteit

Ingestapt Contrarian Investing (David Dreman)
Mar 24, 2026
Ingestapt Defensive Investing (Benjamin Graham)
Mar 24, 2026